Dispensed: A big week for digital health IPOs, what happens when a $2.1 million drug can't get to the kids who need it, and what a top health-tech VC is looking to invest in

Hello, Welcome to Dispensed, Business Insider’s weekly newsletter bringing you all the stories that kept our healthcare team busy this week. WhileErin Brodwin’s been out…

Read More Dispensed: A big week for digital health IPOs, what happens when a $2.1 million drug can't get to the kids who need it, and what a top health-tech VC is looking to invest in

Flare Capital just raised $255 million, and the buzzy VC firm's cofounder told us he wants to invest in companies trying to reinvent the way we get healthcare in the US

Flare Capital Partners raised $255 million in its latest fund and cofounder Michael Greeley told us what he wants to invest in next. Greeley said…

Read More Flare Capital just raised $255 million, and the buzzy VC firm's cofounder told us he wants to invest in companies trying to reinvent the way we get healthcare in the US

'Like we were being forced to gamble with our son's life': Health insurers won't pay for a $2.1 million drug for kids, and parents say they're running out of time

A new type of therapy that treats a devastating inherited disease at the genetic level was recently approved in the US. Its$2.1 million price tag…

Read More 'Like we were being forced to gamble with our son's life': Health insurers won't pay for a $2.1 million drug for kids, and parents say they're running out of time